- In January 2025, Thermo Fisher Scientific, Inc. announced the launch of its new advanced oxidative stress assay kits, designed to enable more accurate detection of oxidative damage in biological samples. These assays utilize cutting-edge detection technologies such as high-content screening and enzyme-linked immunosorbent assays (ELISA) to improve sensitivity and precision, providing enhanced capabilities for researchers and clinicians in oxidative stress studies related to cardiovascular diseases, diabetes, and cancer
- In October 2024, QIAGEN N.V. presented their latest advancements in oxidative stress testing technology at the international bioanalysis conference. The company introduced an innovative series of oxidative stress biomarkers, designed for more efficient and reliable screening of reactive oxygen species (ROS) in clinical research settings. These tools are poised to enhance the ability of researchers to understand the role of oxidative stress in chronic diseases
- In September 2024, Enzo Biochem, Inc. unveiled new data at the 22nd International Conference on Antioxidants and Redox Biology, highlighting the effectiveness of their oxidative stress assays in diagnosing and monitoring lung diseases. Their next-generation assays, including the highly anticipated Antioxidant Capacity Assays, offer improved accuracy in assessing oxidative damage in patients suffering from chronic obstructive pulmonary disease (COPD) and asthma.
- In September 2024, BioVision, Inc. announced the upcoming launch of their updated Reactive Oxygen Species (ROS)-based assay kits. With superior sensitivity and faster processing times, these assays aim to meet the growing demand in the research community for tools that accurately measure ROS levels in cancer research and metabolic disease studies. The new kits are expected to be commercially available in Q1 2025
